



Published Articles - Pulmonary / Respiratory

Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial, Bojke L;Sculpher M;Stephens R;Qian W;Thatcher N;Girling D;, 2006, *Pharmacoeconomics*, 24

Effectiveness of increasing the dose-intensity of chemotherapy with Granulocyte Colony-Stimulating Factor (G-CSF) in small cell lung cancer, based on data from the Medical Research Council LU 19 trial., Bojke L;Sculpher M;Stephens R;Qian W;Thatcher N;Girling D;, 2006, *Pharmacoeconomics*, 24

Cost-effectiveness of asthma control: an economic appraisal of the GOAL study, Briggs AH;Bousquet J;Wallace MV;Busse WW;Clark TJ;Pedersen SE;Bateman ED;, 2006, *Allergy*, 61

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data, Briggs AH;Lozano-Ortega G;Spencer S;Bale G;Spencer MD;Burge PS;, 2006, *Value Health*, 9

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review, Clegg A;Scott DA;Hewitson P;Sidhu M;Waugh N;, 2002, *Thorax*, 57

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer, Clegg A;Scott DA;Sidhu M;Hewitson P;Waugh N;, 2001, *Health Technol Assess*, 5

Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries, Flood EM;De CE;Mork AC;Revicki DA;, 2006, *Health Qual Life Outcomes*, 4

Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization, Gagnon YM;Levy AR;Spencer MD;Hurley JS;Frost FJ;Mapel DW;Briggs AH;, 2005, *Respir Med*, 99

No Study Left Behind: A Network Meta-Analysis in Non-Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data, Hawkins N;Scott DA;Woods BS;Thatcher N;, 2009, *Value Health*,

Transcranial Doppler-directed Dextran-40 therapy is a cost-effective method of preventing carotid thrombosis after carotid endarterectomy, Hayes PD;Lloyd AJ;Lennard N;Wolstenholme JL;London NJ;Bell PR;Naylor AR;, 2000, *Eur J Vasc Endovasc Surg*, 19

Patients' thromboembolic potential between bilateral carotid endarterectomies remains stable over time, Hayes PD;Payne D;Lloyd AJ;Bell PR;Naylor AR;, 2001, *Eur J Vasc Endovasc Surg*, 22

The cost-implications of an asthma attack, Hoskins G;Smith B;Thompson C;Sculpher MJ;, 1998, *Pediatric Asthma, Allergy and Immunology*, 12

Understanding the patient's perspective of asthma control., Kievit P;Sculpher MJ;, 2004, *European Respiratory review*, 13

Coding accuracy of administrative drug claims in the Ontario Drug Benefit database, Levy AR;O'Brien BJ;Sellors C;Grootendorst P;Willison D;, 2003, Can J Clin Pharmacol, 10

Preferences and utilities for the symptoms of moderate to severe allergic asthma, Lloyd A; Doyle S;Dewilde S;Turk F;, 2008, Eur J Health Econ, 9

Patient preferences for asthma therapy: a discrete choice experiment, Lloyd A; McIntosh E;Rabe KF;Williams A;, 2007, Prim Care Respir J, 16

How does patient's quality of life guide their preferences regarding aspects of asthma therapy?, Lloyd A; McIntosh E;Williams A;Kaptein A;Rabe KF;, 2008, Patient, 0.25625

The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK, Lloyd A; Price D;Brown R;, 2007, Prim Care Respir J, 16

Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate to severe allergic asthma, Lloyd A; Turk F;Leighton T;Canonica GW;, 2007, J Med Econ, 10

Prevalence of true vein graft aneurysms: implications for aneurysm pathogenesis, Loftus IM; McCarthy MJ;Lloyd A;Naylor AR;Bell PR;Thompson MM;, 1999, J Vasc Surg, 29

A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome, McDaid C;Duree KH;Griffin SC;Weatherly HL;Stradling JR;Davies RJ;Sculpher MJ;Westwood ME;, 2009, Sleep Med Rev,

Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis, McDaid C;Griffin S;Weatherly H;Duree K;van der BM;van HS;Akers J;Davies RJ;Sculpher M;Westwood M;, 2009, Health Technol Assess, 13

Determinants of hospital length of stay among patients with pneumonia admitted to a large Canadian hospital from 1991 to 2001, McGregor MJ;Fitzgerald JM;Reid RJ;Levy AR;Schulzer M;Jung D;Groshaus HE;Cox MB;, 2005, Can Respir J, 12

Socioeconomic status and hospital utilization among younger adult pneumonia admissions at a Canadian hospital, McGregor MJ;Reid RJ;Schulzer M;Fitzgerald JM;Levy AR;Cox MB;, 2006, BMC Health Serv Res, 6

Health state utilities for non small cell lung cancer, Nafees B;Stafford M;Gavriel S;Bhalla S;Watkins J;, 2008, Health Qual Life Outcomes, 6

Effect of nicotine replacement and quitting smoking on circulating adhesion molecule profiles (sICAM-1, sCD44v5, sCD44v6), Palmer RM;Stapleton JA;Sutherland G;Coward PY;Wilson RF;Scott DA;, 2002, Eur J Clin Invest, 32

Mechanisms of action of environmental factors--tobacco smoking, Palmer RM;Wilson RF;Hasan AS;Scott DA;, 2005, J Clin Periodontol, 32 Suppl 6

Development of an economic model to assess the cost effectiveness of asthma management strategies, Price MJ;Briggs AH;, 2002, Pharmacoeconomics, 20

Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: a western view, Punekar YS;Rodriguez-Roisin R;Sculpher M;Jones P;Spencer M;, 2007, Respir Med, 101

Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease, Sculpher M;, 2001, Pharmacoeconomics, 19 Suppl 2

The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy, Sculpher MJ;Buxton MJ;, 1993, Pharmacoeconomics, 4

Measuring costs and consequences in economic evaluation in asthma, Sculpher MJ;Price M;, 2003, Respir Med, 97

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease, Spencer M;Briggs AH;Grossman RF;Rance L;, 2005, Pharmacoeconomics, 23

Pharmacoeconomics in COPD: lessons for the future, Starkie HJ;Briggs AH;Chambers MG;, 2008, Int J Chron Obstruct Pulmon Dis, 3

An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome, Weatherly HL;Griffin SC;Mc DC;Duree KH;Davies RJ;Stradling JR;Westwood ME;Sculpher MJ;, 2009, Int J Technol Assess Health Care, 25